PARP1 and endometrial cancer: The aforementioned shreds of evidence clubbed with assertions claiming that multifunctional scaffolds can eliminate the need for extensive investigations required for combination therapy, the theoretical basis of the present study was formulated to design dual PARP-Tubulin inhibitors, anticipating promising efficacy of the adducts in endometrial cancer.